NACC2

Across TCGA pan-cancer cohorts, NACC2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of NACC2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where NACC2 RNA is repressed in tumor relative to normal tissue. In most cancer types NACC2 is over-expressed in tumor, although a few such as BLCA and UCEC show the opposite, repressed pattern.

BLCA, LIHC, and UCEC are the cancer types where NACC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NACC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−3.120	<.001	11	view →
LIHC	Female	II,III,IV	+1.214	<.001	8	view →
UCEC	All	All	−1.854	<.001	6	view →
LUSC	All	II,III,IV	−0.933	<.001	6	view →
BRCA	All	II,III,IV	−0.628	<.001	6	view →
KIRC	Male	II,III,IV	−0.414	.001	6	view →
CHOL	All	All	+1.898	<.001	5	view →
LUAD	Female	All	−0.742	<.001	5	view →
COAD	Male	All	−0.589	.013	3	view →
STAD	Female	All	−1.188	.038	2	view →
READ	All	All	−1.061	.004	2	view →
PRAD	All	All	−0.568	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

NACC2–BLCA

Open the BLCA breakdown →